Potential nonhormonal therapeutics for medical treatment of leiomyomas

Seminars in Reproductive Medicine

Volumn 22, Issue 2, 2004, Pages 121-130

  Young, Steven L ^a   Al Hendy, Ayman ^b   Copland, John A ^c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

^c MAYO CLINIC   (United States)

Author keywords

Alpha tocopherol succinate; Apoptosis; Leiomyoma; Thiazolidinedione; Tocopherol

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETIC ACID DERIVATIVE; ALPHA INTERFERON; ALPHA TOCOPHEROL; ALPHA TOCOPHEROL DERIVATIVE; ANTIGESTAGEN; BEXAROTENE; COLLAGEN; DANAZOL; ESTROGEN; FIBRONECTIN; GESTAGEN; GESTRINONE; GONADORELIN DERIVATIVE; GROWTH FACTOR; HALOFUGINONE; HEPARIN; MIFEPRISTONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIRFENIDONE; POLY 4 HYDROXYPHENOXYACETIC ACID; PROGESTERONE; PROGESTERONE RECEPTOR MODULATOR; RG 13577; ROSIGLITAZONE; SOMATOMEDIN; TOCOPHEROL DERIVATIVE; TRANILAST; TRANSFORMING GROWTH FACTOR BETA; TROGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTIFICIAL EMBOLISM; AUTOIMMUNE DISEASE; BLEEDING; BONE MARROW SUPPRESSION; CATARACT; DIZZINESS; DRUG EFFICACY; FATIGUE; FEMALE; FIBROSING ALVEOLITIS; GASTROINTESTINAL SYMPTOM; HEADACHE; HORMONAL THERAPY; HOT FLUSH; HUMAN; HYPERKALEMIA; HYSTERECTOMY; LEUKOPENIA; LIVER DISEASE; LIVER TOXICITY; MORBIDITY; MORTALITY; MYOMECTOMY; NONHUMAN; OSTEOPOROSIS; OVARY DISEASE; PANCREATITIS; RASH; REPRODUCTION; REVIEW; TERATOGENICITY; THROMBOCYTOPENIA; THYROID DISEASE; UPPER RESPIRATORY TRACT INFECTION; UTERUS MYOMA; VAGINA ATROPHY; WEIGHT GAIN;

ANTHRANILIC ACIDS; FEMALE; HEPARIN; HUMANS; INTERFERON-ALPHA; LEIOMYOMA; PIPERIDINES; PYRIDONES; QUINAZOLINES; QUINAZOLINONES; REPRODUCTION; TETRAHYDRONAPHTHALENES; THIAZOLIDINEDIONES; TOCOPHEROLS; UTERINE NEOPLASMS;

EID: 2542503396     PISSN: 15268004     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-828618     Document Type: Review

References (82)

1. Buttram VC Jr, Reiter RC. Uterine leiomyomata: etiology, symptomatology, and management. Fertil Steril 1981;36: 433-445
2. Candiani GB, Fedele L, Parazzini F, Villa L. Risk of recurrence after myomectomy. Br J Obstet Gynaecol 1991;98: 385-389
3. Fedele L, Parazzini F, Luchini L, Mezzopane R, Tozzi L, Villa L. Recurrence of fibroids after myomectomy: a transvaginal ultrasonographic study. Hum Reprod 1995;10: 1795-1796
4. Guarnaccia MM, Rein MS. Traditional surgical approaches to uterine fibroids: abdominal myomectomy and hysterectomy. Clin Obstet Gynecol 2001;44:385-400
5. Keshavarz H, Hillis SD, Kieke BA, Marchbanks PA. Hysterectomy surveillance-United States, 1994-1999. Surveillance Summaries, July 12, 2002. MMWR Morb Mortal Wkly Rep 2002;51:1-8
6. Spies JB, Spector A, Roth AR, Baker CM, Mauro L, Murphy-Skrynarz K. Complications after uterine artery embolization for leiomyomas. Obstet Gynecol 2002;100: 873-880
7. Chrisman HB, Saker MB, Ryu RK, et al. The impact of uterine fibroid embolization on resumption of menses and ovarian function. J Vasc Interv Radiol 2000;11:699-703
8. Carr BR, Marshburn PB, Weatherall PT, et al. An evaluation of the effect of gonadotropin-releasing hormone analogs and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: a prospective, randomized, double blind, placebo-controlled, crossover trial. J Clin Endocrinol Metab 1993;76:1217-1223
9. Murphy AA, Morales AJ, Kettel LM, Yen SS. Regression of uterine leiomyomata to the antiprogesterone RU486: dose-response effect. Fertil Steril 1995;64:187-190
10. Stewart EA. Treatment of uterine leiomyomas. In: Rose BD, ed. UpToDate. Wellesley, MA: UpToDate; 2003
11. De Leo V, la Marca A, Morgante G. Short-term treatment of uterine fibromyomas with danazol. Gynecol Obstet Invest 1999;47:258-262
12. Ueki M, Okamoto Y, Tsurunaga T, Seiki Y, Ueda M, Sugimoto O. Endocrinological and histological changes after treatment of uterine leiomyomas with danazol or buserelin. J Obstet Gynaecol 1995;21:1-7
13. Nowak RA. Novel therapeutic strategies for leiomyomas: targeting growth factors and their receptors. Environ Health Perspect 2000;108(suppl 5):849-853
14. Lee BS, Margolin SB, Nowak RA. Pirfenidone: a novel pharmacological agent that inhibits leiomyoma cell proliferation and collagen production. J Clin Endocrinol Metab 1998; 83:219-223
15. Lee BS, Stewart EA, Sahakian M, Nowak RA. Interferon-alpha is a potent inhibitor of basic fibroblast growth factor-stimulated cell proliferation in human uterine cells. Am J Reprod Immunol 1998;40:19-25
16. Lee BS, Nowak RA. Human leiomyoma smooth muscle cells show increased expression of transforming growth factor-beta 3 (TGF beta 3) and altered responses to the antiproliferative effects of TGF beta. J Clin Endocrinol Metab 2001;86:913-920
17. Nowak RA. Identification of new therapies for leiomyomas: what in vitro studies can tell us. Clin Obstet Gynecol 2001; 44:327-334
18. Gamage SD, Bischoff ED, Burroughs KD, et al. Efficacy of LGD1069 (Targretin), a retinoid X receptor-selective ligand, for treatment of uterine leiomyoma. J Pharmacol Exp Ther 2000;295:677-681
19. Shime H, Kariya M, Orii A, et al. Tranilast inhibits the proliferation of uterine leiomyoma cells in vitro through G1 arrest associated with the induction of p21(waf1) and p53. J Clin Endocrinol Metab 2002;87:5610-5617
20. Young S, Copland J. Vitamin E is a potent inhibitor of leiomyoma cell growth. J Soc Gynecol Investig 1999;6(suppl):230A
21. Young S, Goluszko P, Taglialatela G, Copland J. A central role for protein kinase C in growth and death of leiomyoma cells: modulation by α-tocopherol succinate. J Soc Gynecol Investig 2000;7(suppl):132A
22. Raghu G, Johnson WC, Lockhart D, Mageto Y. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label phase II study. Am J Respir Crit Care Med 1999;159:1061-1069
23. Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on procollagen gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther 1999;289:211-218
24. Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther 1999;291:367-373
25. Hewitson TD, Kelynack KJ, Tait MG, et al. Pirfenidone reduces in vitro rat renal fibroblast activation and mitogenesis. J Nephrol 2001;14:453-460
26. Nagler A, Miao HQ, Aingorn H, Pines M, Genina O, Vlodavsky I. Inhibition of collagen synthesis, smooth muscle cell proliferation, and injury-induced intimal hyperplasia by halofuginone. Arterioscler Thromb Vasc Biol 1997;17:194-202
27. Elkin M, Ariel I, Miao HQ, et al. Inhibition of bladder carcinoma angiogenesis, stromal support, and tumor growth by halofuginone. Cancer Res 1999;59:4111-4118
28. Kliewer SA, Umesono K, Mangelsdorf DJ, Evans RM. Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signalling. Nature 1992;355:446-449
29. Kliewer SA, Umesono K, Noonan DJ, Heyman RA, Evans RM. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 1992;358:771-774
30. Bischoff ED, Gottardis MM, Moon TE, Heyman RA, Lamph WW. Beyond tamoxifen: the retinold X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma. Cancer Res 1998;58:479-484
31. Everitt JI, Wolf DC, Howe SR, Goldsworthy TL, Walker C. Rodent model of reproductive tract leiomyomata. Clinical and pathological features. Am J Pathol 1995;146:1556-1567
32. Howe SR, Everitt JL, Gottardis MM, Walker C. Rodent model of reproductive tract leiomyomata: characterization and use in preclinical therapeutic studies. Prog Clin Biol Res 1997;396:205-215
33. Miyazawa K, Kikuchi S, Fukuyama J, Hamano S, Ujiie A. Inhibition of PDGF- and TGF-beta 1-induced collagen synthesis, migration and proliferation by tranilast in vascular smooth muscle cells from spontaneously hypertensive rats. Atherosclerosis 1995;118:213-221
34. Fukuyama J, Miyazawa K, Hamano S, Ujiie A. Inhibitory effects of tranilast on proliferation, migration, and collagen synthesis of human vascular smooth muscle cells. Can J Physiol Pharmacol 1996;74:80-84
35. Yamada H, Tajima S, Nishikawa T. Tranilast inhibits collagen synthesis in normal, scleroderma and keloid fibroblasts at a late passage culture but not at an early passage culture. J Dermatol Sci 1995;9:45-47
36. Horiuchi A, Nikaido T, Ya-Li Z, Ito K, Orii A, Fujii S. Heparin inhibits proliferation of myometrial and leiomyomal smooth muscle cells through the induction of alpha-smooth muscle actin, calponin h1 and p27. Mol Hum Reprod 1999;5:139-145
37. Tamai H, Katoh K, Yamaguchi T, et al. The impact of tranilast on restenosis after coronary angioplasty: the Second Tranilast Restenosis Following Angioplasty Trial (TREAT-2). Am Heart J 2002;143:506-513
38. Bono F, Rigon P, Lamarche I, Savi P, Salel V, Herbert JM. Heparin inhibits the binding of basic fibroblast growth factor to cultured human aortic smooth-muscle cells. Biochem J 1997;326:661-668
39. Reilly CF, Fritze LM, Rosenberg RD. Heparin-like molecules regulate the number of epidermal growth factor receptors on vascular smooth muscle cells. J Cell Physiol 1988;136:23-32
40. Lapierre F, Holme K, Lam L, et al. Chemical modifications of heparin that diminish its anticoagulant but preserve its heparanase-inhibitory, angiostatic, anti-tumor and antimetastatic properties. Glycobiology 1996;6:355-366
41. Mason HR, Nowak RA, Morton CC, Castellot JJ Jr. Heparin inhibits the motility and proliferation of human myometrial and leiomyoma smooth muscle cells. Am J Pathol 2003; 162:1895-1904
42. Benezra M, Ben-Sasson SA, Regan J, Chang M, Bar-Shavit R, Vlodavsky I. Antiproliferative activity to vascular smooth muscle cells and receptor binding of heparin-mimicking polyaromatic anionic compounds. Arterioscler Thromb 1994; 14:1992-1999
43. Tredget EE, Wang R, Shen Q, Scott PG, Ghahary A. Transforming growth factor-beta mRNA and protein in hypertrophic scar tissues and fibroblasts: antagonism by IFN-alpha and IFN-gamma in vitro and in vivo. J Interferon Cytokine Res 2000;20:143-151
44. Ghahary A, Shen Q, Rogers JA, et al. Liposome-associated interferon-alpha-2b functions as an anti-fibrogenic factor for human dermal fibroblasts. J Invest Dermatol 1997;109: 55-60
45. Minakuchi K, Kawamura N, Tsujimura A, Ogita S. Remarkable and persistent shrinkage of uterine leiomyoma associated with interferon alfa treatment for hepatitis. Lancet 1999;353:2127-2128
46. Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology 1997;26:112S-121S
47. Tsibris JC, Porter KB, Jazayeri A, et al. Human uterine leiomyomata express higher levels of peroxisome proliferator-activated receptor gamma, retinoid X receptor alpha, and all-trans retinoic acid than myometrium. Cancer Res 1999;59: 5737-5744
48. Houston KD, Copland JA, Broaddus RR, Gottardis MM, Fischer SM, Walker CL. Inhibition of proliferation and estrogen receptor signaling by peroxisome proliferator-activated receptor gamma ligands in uterine leiomyoma. Cancer Res 2003;63:1221-1227
49. Porter KB, Tsibris JC, Porter GW, et al. Effects of raloxifene in a guinea pig model for leiomyomas. Am J Obstet Gynecol 1998;179:1283-1287
50. Fayed YM, Tsibris JC, Langenberg PW, Robertson AL Jr. Human uterine leiomyoma cells: binding and growth responses to epidermal growth factor, platelet-derived growth factor, and insulin. Lab Invest 1989;60:30-37
51. Fujiwara T, Horikoshi H. Troglitazone and related compounds: therapeutic potential beyond diabetes. Life Sci 2000;67:2405-2416
52. Bunyan J, Green J, Diplock AT, Robinson D. Lysosomal enzymes and vitamin E deficiency. II. Gestation-resorption in the rat. Br J Nutr 1967;21:137-145
53. Csallany AS, Ayaz KL, Su LC. Effect of dietary vitamin E and aging on tissue lipofuscin pigment concentration in mice. J Nutr 1977;107:1792-1799
54. Csallany AS, Ayaz KL, Menken BZ. Effect of dietary vitamin E upon fluorescent compounds of the rat uterus. Lipids 1984;19:911-915
55. Desai ID, Fletcher BL, Tappel AL. Fluorescent pigments from uterus of vitamin E-deficient rats. Lipids 1975;10:307-309
56. Evans DJ, Berney DM, Pollock DJ. Symptomatic vitamin E deficiency diagnosed after histological recognition of myometrial lipofuscinosis. Lancet 1995;346:545-546
57. Tasinato A, Boscoboinik D, Bartoli GM, Maroni P, Azzi A. d-alpha-Tocopherol inhibition of vascular smooth muscle cell proliferation occurs at physiological concentrations, correlates with protein kinase C inhibition, and is independent of its antioxidant properties. Proc Natl Acad Sci U S A 1995;92: 12190-12194
58. Card JW, Leeder RG, Racz WJ, Brien JF, Bray TM, Massey TE. Effects of dietary vitamin E supplementation on pulmonary morphology and collagen deposition in amiodarone- and vehicle-treated hamsters. Toxicology 1999;133: 75-84
59. Delanian S, Porcher R, Balla-Mekias S, Lefaix JL. Randomized, placebo-controlled trial of combined pentoxifylline and tocopherol for regression of superficial radiation-induced fibrosis. J Clin Oncol 2003;21:2545-2550
60. Kilinc C, Ozcan O, Karaoz E, Sunguroglu K, Kutluay T, Karaca L. Vitamin E reduces bleomycin-induced lung fibrosis in mice: biochemical and morphological studies. J Basic Clin Physiol Pharmacol 1993;4:249-269
61. Denis M. Antioxidant therapy partially blocks immune-induced lung fibrosis. Inflammation 1995;19:207-219
62. Card JW, Racz WJ, Brien JF, Massey TE. Attenuation of amiodarone-induced pulmonary fibrosis by vitamin E is associated with suppression of transforming growth factor-beta1 gene expression but not prevention of mitochondrial dysfunction. J Pharmacol Exp Ther 2003;304:277-283
63. Malafa MP, Fokum FD, Mowlavi A, Abusief M, King M. Vitamin E inhibits melanoma growth in mice. Surgery 2002;131:85-91
64. Fariss MW, Fortuna MB, Everett CK, Smith JD, Trent DF, Djuric Z. The selective antiproliferative effects of alpha-tocopheryl hemisuccinate and cholesteryl hemisuccinate on murine leukemia cells result from the action of the intact compounds. Cancer Res 1994;54:3346-3351
65. Israel K, Sanders BG, Kline K. RRR-alpha-tocopheryl succinate inhibits the proliferation of human prostatic tumor cells with defective cell cycle/differentiation pathways. Nutr Cancer 1995;24:161-169
66. Israel K, Yu W, Sanders BG, Kline K. Vitamin E succinate induces apoptosis in human prostate cancer cells: role for Fas in vitamin E succinate-triggered apoptosis. Nutr Cancer 2000;36:90-100
67. Neuzil J, Weber T, Terman A, Weber C, Brunk UT. Vitamin E analogues as inducers of apoptosis: implications for their potential antineoplastic role. Redox Rep 2001;6:143-151
68. Neuzil J, Weber T, Schroder A, et al. Induction of cancer cell apoptosis by alpha-tocopheryl succinate: molecular pathways and structural requirements. FASEB J 2001;15:403-415
69. Neuzil J. Alpha-tocopheryl succinate epitomizes a compound with a shift in biological activity due to pro-vitamin-to-vitamin conversion. Biochem Biophys Res Commun 2002; 293:1309-1313
70. Neuzil J, Kagedal K, Andera L, Weber C, Brunk UT. Vitamin E analogs: a new class of multiple action agents with anti-neoplastic and anti-atherogenic activity. Apoptosis 2002; 7:179-187
71. Rose AT, McFadden DW. Alpha-tocopherol succinate inhibits growth of gastric cancer cells in vitro. J Surg Res 2001;95:19-22
72. Turley JM, Fu T, Ruscetti FW, Mikovits JA, Bertolette DC III, Birchenall-Roberts MC. Vitamin E succinate induces Fas-mediated apoptosis in estrogen receptor-negative human breast cancer cells. Cancer Res 1997;57:881-890
73. You H, Yu W, Sanders BG, Kline K. RRR-alpha-tocopheryl succinate induces MDA-MB-435 and MCF-7 human breast cancer cells to undergo differentiation. Cell Growth Differ 2001;12:471-480
74. Yu W, Sanders BG, Kline K. RRR-alpha-tocopheryl succinate inhibits EL4 thymic lymphoma cell growth by inducing apoptosis and DNA synthesis arrest. Nutr Cancer 1997;27:92-101
75. Turley JM, Ruscetti FW, Kim SJ, Fu T, Gou FV, Birchenall-Roberts MC. Vitamin E succinate inhibits proliferation of BT-20 human breast cancer cells: increased binding of cyclin A negatively regulates E2F transactivation activity. Cancer Res 1997;57:2668-2675
76. Neuzil J, Weber T, Gellert N, Weber C. Selective cancer cell killing by alpha-tocopheryl succinate. Br J Cancer 2001;84: 87-89
77. Zhang Y, Ni J, Messing EM, Chang E, Yang CR, Yeh S. Vitamin E succinate inhibits the function of androgen receptor and the expression of prostate-specific antigen in prostate cancer cells. Proc Natl Acad Sci U S A 2002;99: 7408-7413
78. Kitagawa M, Mino M. Effects of elevated d-alpha(RRR)-tocopherol dosage in man. J Nutr Sci Vitaminol (Tokyo) 1989;35:133-142
79. Morinobu T, Ban R, Yoshikawa S, Murata T, Tamai H. The safety of high-dose vitamin E supplementation in healthy Japanese male adults. J Nutr Sci Vitaminol (Tokyo) 2002; 48:6-9
80. Meydani SN, Meydani M, Blumberg JB, et al. Assessment of the safety of supplementation with different amounts of vitamin E in healthy older adults. Am J Clin Nutr 1998;68: 311-318
81. Farrell PM, Bieri JG. Megavitamin E supplementation in man. Am J Clin Nutr 1975;28:1381-1386
82. Cheeseman KH, Holley AE, Kelly FJ, Wasil M, Hughes L, Burton G. Biokinetics in humans of RRR-alpha-tocopherol: the free phenol, acetate ester, and succinate ester forms of vitamin E. Free Radic Biol Med 1995;19:591-598